Newsletter
Newsletter November 2017
CEO comments I am currently putting the finishing touches to the list of meetings we have booked with companies at Bio Europe in Berlin, which is being held from Monday to Wednesday this week. Bio Europe is a major...
Read MoreNewsletter August 2017
CEO comments I hope that you all have had a chance to enjoy some sunshine and warm days in July. Cyxone, in collaboration with our partners, has been working even during the month of July to ensure that the...
Read MoreNewsletter July 2017
CEO’s comments Positive comments and questions about Cyxone, T20K and Rabeximod continue to flood in. I am grateful for all the interest, and felt that in this newsletter I would try to offer a little more background so that...
Read MoreNewsletter June 2017
CEO’s comments We have received many positive reactions and relevant questions since we announced our plans to acquire Phase II substance Rabeximod from OxyPharma. Naturally, a brief media release cannot provide comprehensive information about all the various aspects related...
Read MoreNewsletter April 2017
CEO’s comments I hope that you have all had a happy and pleasant Easter, even if the weather was rather patchy at times. In March and April, Cyxone, together with researchers in Vienna, Freiburg and our strategic partner Sourcia,...
Read MoreNewsletter March 2017
This issue of the newsletter is a little later than planned due to two international events, Swiss Nordic Bio and Sachs Forum, which were held in the past two months. Because I presented Cyxone and how T20K can combat...
Read MoreNewsletter February 2017
A message from the CEO We learnt a great deal about T20K in 2016! Over the past six months, we have analysed a number of T20K’s key characteristics according to the plans we announced prior to floatation in June...
Read MoreNewsletter January 2017
CEO comments December has been very busy due to Christmas holidays and because many results had to be brought in from our collaborative partners to start our planning for year 2017. Thanks to Cyxone’s new project manager Leonard Saffer,...
Read MoreNewsletter December 2016
Message from the CEO The month began with BioEurope in Cologne, where we had meetings with new pharmaceutical companies and companies that can coordinate Cyxone’s regulatory studies (CROs). I met representatives from pharmaceutical companies that are very active in...
Read MoreNewsletter November 2016
Message from the CEO I am really pleased with the number of people who show an interest in Cyxone, what we are doing, and the progress of T20K. A lot of people communicate with me, and although I try...
Read More